糖尿病患者乳腺癌、宫颈癌和结直肠癌筛查的系统综述与荟萃分析
结果显示糖尿病患者乳腺癌筛查(调整OR 0.83,95%CI 0.77-0.90)和宫颈癌筛查(OR 0.76,95%CI 0.71-0.81)的可能性显著较低,结直肠癌筛查总体相当(OR 0.95,95%CI 0.86-1.06),但女性糖尿病患者结直肠癌筛查可能性较低(OR 0.86,95%CI 0.77-0.97)。
要点
- 糖尿病患者乳腺癌筛查可能性显著低于非糖尿病者(调整OR 0.83,95%CI 0.77-0.90)。
- 糖尿病患者宫颈癌筛查可能性显著低于非糖尿病者(OR 0.76,95%CI 0.71-0.81)。
- 女性糖尿病患者结直肠癌筛查可能性低于非糖尿病女性(OR 0.86,95%CI 0.77-0.97)。
核心结论
- 女性糖尿病患者乳腺癌、宫颈癌和结直肠癌筛查率低于非糖尿病女性,但绝对差异可能不大。
- 鉴于该人群癌症风险增加,需要更高质量的前瞻性证据评估糖尿病对癌症筛查差异的贡献。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE和CINAHL数据库1997年1月1日至2018年7月18日发表的文献。
- 纳入标准:一般人群研究;糖尿病作为预测因素与非糖尿病对照组比较;乳腺癌(乳腺X线摄影)、宫颈癌(巴氏涂片)或结直肠癌(粪便和內镜检测)筛查参与度作为结局。
- 采用随机效应荟萃分析,使用每个癌症部位的最调整估计值。
- PROSPERO注册号CRD42017073107。
主要发现
- 糖尿病与乳腺癌筛查可能性显著降低相关(调整OR 0.83,95%CI 0.77-0.90)。
- 糖尿病与宫颈癌筛查可能性显著降低相关(OR 0.76,95%CI 0.71-0.81)。
- 结直肠癌筛查在糖尿病组与非糖尿病组间总体相当(OR 0.95,95%CI 0.86-1.06)。
- 女性糖尿病患者结直肠癌筛查可能性低于非糖尿病女性(OR 0.86,95%CI 0.77-0.97)。
临床怎么用
- 内分泌科医生应关注女性糖尿病患者的乳腺癌、宫颈癌和结直肠癌筛查参与情况,必要时提醒并促进其完成筛查。
局限性
- 纳入研究以横断面设计为主,难以确定因果关系。
- 绝对差异可能不大,需结合其他患者、提供者和系统层面因素综合解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Individuals with diabetes are at increased risk of developing and dying from cancer. Evidence-based guidelines recommend universal screening for breast, cervical and colorectal cancer; however, evidence on the uptake of these tests in individuals with diabetes is mixed. We conducted a meta-analysis to quantify the association between diabetes and participation in breast, cervical and colorectal cancer screening. METHODS: MEDLINE, EMBASE and CINAHL were searched systematically for publications between 1 January 1997 and 18 July 2018. The search was supplemented by handsearching of reference lists of the included studies and known literature reviews. Abstracts and full texts were assessed in duplicate according to the following eligibility criteria: study conducted in the general population; diabetes included as a predictor vs a comparison group without diabetes; and breast (mammography), cervical (Papanicolaou smear) or colorectal (faecal and endoscopic tests) cancer screening uptake included as an outcome. Random-effects meta-analyses were performed using the most-adjusted estimates for each cancer site. RESULTS: Thirty-seven studies (25 cross-sectional, 12 cohorts) were included, with 27 studies on breast, 19 on cervical and 18 on colorectal cancer screening. Having diabetes was associated with significantly lower likelihood of breast (adjusted OR 0.83 [95% CI 0.77, 0.90]) and cervical (OR 0.76 [95% CI 0.71, 0.81]) cancer screening, relative to not having diabetes. Colorectal cancer screening was comparable across groups with and without diabetes (OR 0.95 [95% CI 0.86, 1.06]); however, women with diabetes were less likely to receive a colorectal cancer screening test than women without diabetes (OR 0.86 [95% CI 0.77, 0.97]). CONCLUSIONS/INTERPRETATION: Our findings suggest that women with diabetes have suboptimal breast, cervical and colorectal cancer screening rates, compared with women without diabetes, although the absolute differences might be modest. Given the increased risk of cancer in this population, higher quality prospective evidence is necessary to evaluate the contribution of diabetes to cancer screening disparities in relation to other patient-, provider- and system-level factors. REGISTRATION: PROSPERO registration ID CRD42017073107.
引用
- Bhatia D, Lega IC, Wu W, et al. Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis. Diabetologia. 2019. PMID: 31650239. doi:10.1007/s00125-019-04995-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。